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The polymorphic P450 (CYP) enzyme superfamily is the most important system involved in the 
biotransformation of many endogenous and exogenous substances including drugs, toxins, and carcinogens. 
Genotyping for CYP polymorphisms provides important genetic information that help to understand the 
effects of xenobiotics on human body. For drug metabolism, the most important polymorphisms are those 
of the genes coding for CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5, which can result in therapeutic 
failure or severe adverse reactions. Genes coding for CYP1A1, CYP1A2, CYP1B1, and CYP2E1 are among 
the most responsible for the biotransformation of chemicals, especially for the metabolic activation of 
pre-carcinogens. There is evidence of association between gene polymorphism and cancer susceptibility. 
Pathways of carcinogen metabolism are complex, and are mediated by activities of multiple genes, while 
single genes have a limited impact on cancer risk. Multigenic approach in addition to environmental 
determinants in large sample studies is crucial for a reliable evaluation of any moderate gene effect. This 
article brings a review of current knowledge on the relations between the polymorphisms of some CYPs 
and drug activity/toxicity and cancer risk.
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The traditional toxicity assessment has been 
using descriptive means, finding links between 
chemicals in different doses and tissue pathology 
at the site of action, system-level toxicity, and overt 
mortality. It has been providing a framework for 
understanding the toxicity of a chemical. Progress in 
biological research calls for the understanding of the 
mechanisms of toxicity at the molecular level. Here 
the essential role is played by genomic information 
at the pharmacokinetic and pharmacodinamic level. 
For example, the genotype of an individual can 
signifi cantly infl uence the disposition of a chemical, 
and determine their susceptibility to its toxicity (1). In 
addition, exposure to chemicals can result in different 
gene expression, which in turn can lead to different 
pharmacodynamic effects. The Human Genome 
Project (HUGO) has provided a number of genetic 
information that helps us understand the effects of 
xenobiotics on biological systems. New scientifi c 
fi elds have developed. Pharmacogenomics studies 
the role of gene variants in interactions between 
drugs and drug-exposed organisms (2-5). Ecogenetics 
investigates dynamic interactions between a specifi c 
individual genotype and different compounds from the 
environment such as industrial chemicals and nutrition 
products (6, 7). Toxicogenomics studies individual 
218
predisposition to carcinogenic, teratogenic, and 
other toxic effects of drugs and other xenobiotics (8). 
Integration of genomics into toxicological research 
can provide a better understanding of how various 
xenobiotics act in the human body (9).
Main proteins involved in xenobiotic disposition 
in the body are classifi ed as either phase I (oxidative), 
or phase II (conjugative) metabolising enzymes, or 
phase III transporters involved in effl ux mechanisms. 
The major enzymes of phase I metabolism are heme 
thiolate proteins of the cytochrome P450 superfamily 
(CYPs).
Phase I enzymes generate functional groups that may 
subsequently serve as a site for conjugation catalysed 
by phase II enzymes UDP-glucuronosyltransferases 
(UGT), Sulfotransferases (SULT), Glutathione S-
transferases (GST), and N-acetiltransferases (NAT). 
These enzyme reactions are necessary fo a lipophilic 
compound to biotransform into a watersoluble product 
that can be excreted in urine. Phase III transporters 
like, P-glycoprotein (Pgp), multidrug resistance-
associated proteins (MRPs), and organic anion 
transporting polypeptide 2 (OATP2) are expressed in 
many tissues such as the liver, intestine, kidney, and 
brain, and play a crucial role in xenobiotic absorption, 
distribution, and excretion. Along with phase I and 
phase II enzyme induction/inhibition, pretreatment 
with different inducers or inhibitors has been shown to 
alter the expression of phase III transporters, with the 
fi nal results of altered excretion of xenobiotics. Orphan 
nuclear receptors like pregnane X-receptor (PXR) and 
constitutive androgen receptor (CAR) are often termed 
“xenosensors”. They interact with various exogenous 
drugs and toxins, and mediate cellular response to 
toxic insult by acting as transcription factors for 
the members of the secretory detoxifi cation system, 
including effl ux transporters and metabolic enzymes 
(10, 11). Exposure to phase I, phase II, and phase III 
inducers may trigger cellular stress response leading 
to increase in gene expression, which ultimately 
enhances the elimination and clearance of these 
xenobiotics.
Chemical carcinogenesis is a complex multistage 
process that includes three main steps: initiation, 
promotion, and progression. Each stage depends 
on a number of factors that can promote or prevent 
carcinogenesis. The genotoxic impact of carcinogen 
exposure is heavily influenced by a complex 
array of metabolic pathways. Carcinogenesis 
induced by genotoxic xenobiotics is related to 
polymorphisms of phase I and phase II enzyme systems 
responsible for metabolic activation/detoxifi cation of 
carcinogenic substances. Along with carcinogen 
dose and exposure time, these factors influence 
the outcome of a malignant process. Carcinogenic 
agents are divided into direct carcinogens such as N-
nitrosoalkylurea, ethyl-and methylmethanesulfonate, 
N-methyl-N-nitronitrosoguanidine, sulphur mustard, 
diepoxybutane, β-propiolactone, and ethyleneimine, 
and procarcinogens which are metabolised in the 
cell in two steps catalysed by various phase I and II 
enzymes. In the fi rst step, procarcinogens are activated 
and converted into electrophilic derivatives. In the 
second step, metabolic products are neutralised by 
conjugation (12). The main activating enzymes 
include CYPs isoforms, and to a lesser degree, 
oxidases, hydroxylases, epoxygenases reductases, 
flavin-containing monooxygenases, peroxidases, 
dehydrogenases, hydrolases, and some other 
enzymes. Conjugation enzymes include epoxidases, 
acyltransferases, sulfotransferases, gluthatione-
S-transferases, UDP-glucuronyl transferases, and 
transaminases. For some carcinogens, second-stage 
reactions are a necessary intermediate step and a 
prerequisite to further activation.
The majority of currently known procarcinogens 
are hydrophobic CYP substrates (Table 1). Most 
hydrophobic substrates are polycyclic aromatic 
hydrocarbons (PAHs), polychlorinated biphenyls, and 
dioxin-like compounds. More hydrophilic compounds 
include nitrosoureas, aminoazo dyes, biphenyls, 
fl uorenes, and heterocyclic amine (13). Some enzymes 
infl uence carcinogenesis indirectly i.e. by metabolising 
a number of endogenous compounds such as sex 
hormones, corticosteroids, cholesterol, bile acids, 
and retinoic acid. Mutations in the corresponding 
genes may promote carcinogenesis and progression 
of tumours (14). Habits like cigarette smoking, are 
yet another source of exposure relevant for cancer 
development in some tissues and organs such as large 
bowel, and lung. Estimations of cancer risk should 
always take into account the interplay between dietary 
habits, environmental exposure, and expression of 
particular isoforms of metabolic enzymes.
CYTOCHROMES P450 (CYPs)
Overview
Among the enzymes of phase I biotransformation, 
CYPs exhibit considerable catalytic diversity. This 
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enzyme superfamily, existing in over 50 forms, is 
the most important enzyme system involved in the 
biotransformation of many endogenous and exogenous 
substances including drugs. CYPs are variably 
distributed in different tissues. Most can be found 
in the membrane of the endoplasmatic reticulum 
in the liver, although CYPs are found in almost all 
tissues and organs (intestine, lung, kidney, brain, 
lymphocytes, and placenta). Physiological substrates 
of these enzymes include steroids, fatty acids, 
prostaglandins, leukotrienes, and biogene amines, 
while xenobiotic substrates include drugs, herbal 
toxins and toxic chemicals from the environment. 
CYPs predominantly catalyse oxidative reactions, 
insertion of an atom from molecular oxygen into a 
substrate, i.e. a typical activating (or Phase I) reaction, 
serving as monooxygenases, oxidases and peroxidases, 
although they can act in reduction reactions too. 
CYPs are divided in three major groups. The fi rst 
includes CYP families 5 to 51 with a high affi nity for 
endogenous substrates, which have remained well 
conserved throughout evolution. The second group 
includes CYP families 1 to 3, that have lower affi nity 
for their substrates and have been less conserved 
evolutionarily. The third group includes CYP family 
4 which metabolise fatty acids, related substrates, and 
some xenobiotics. CYP families 1 to 3 are responsible 
for 70 % to 80 % of all phase I- dependent metabolism 
of clinically used drugs (9), and participate in the 
metabolism of a huge number of xenobiotic chemicals 
(Table 2) (15). Most of the enzymes in CYP families 
1 to 3 exhibit interindividual variability in catalytic 
activity. This is either due to genetic polymorphisms 
or to variability in expression levels.
Each CYP isoform has its own set of metabolised 
substrates. The same xenobiotic can be metabolised by 
different isoforms into similar or different metabolic 
products. For enzymes belonging to CYP families 1 
to 4 overlapping substrate specifi city is known.
The most important enzymes for drug metabolism 
are CYP2C9*, CYP2C19, CYP2D6 and CYP3A4, 
whereas the most important isoforms responsible for 
the biotransformation of chemicals and especially 
for the metabolic activation of pre-carcinogens are 
CYP1A, CYP1A2, CYP1B1, CYP2A6, CYP2E1 and 
again CYP3A4. In CYP families 2 and 3 HUGO has 
found new genes like CYP2R1, CYP2S1, CYP2U1 
and CYP3A43. Their function and importance are 
still investigated.
* Enzymes are written in capital letters, and coding genes in italics.
There is no apparent relationship between the 
amount of hepatic CYPs and their relative importance 
for drug metabolism. This might indicate that highly 
expressed CYPs play an important role in food 
metabolism and a relatively minor role in drug 
metabolism.Most CYP enzymes are preferentially 
expressed in the centrilobular area of the liver (16). 
This has toxicological implications, as the centrilobular 
area is more sensitive to damage by drugs and ethanol, 
which are CYP substrates.
Most CYPs involved in the biotransformation 
of xenobiotics are inducible (17). An exception is 
CYP2D6 in which multiple gene copies are responsible 
for increased detoxifying potential of the enzyme 
(18). Induction is an important adaptive reaction 
against environmental toxins from the past. CYP 
expression can be controlled at the transcriptional, 
mRNA, translational and posttranslational levels. 
Transcriptional control is highly important and three 
crucial cytosolic receptors detect the concentration 
of environmental xenobiotics, namely the pregnane 
X-receptor (PXR), constitutive androgen receptor 
(CAR) and aryl hydrocarbon receptor (AhR). AhR 
regulates CYP1A1, CYP1A2 and CYP2S1; PXR 
regulates CYP2C9 and CYP3A4 and CAR regulates 
CYP2B6, CYP2C9, and CYP3A4. Activation of CYPs 
as well as phase II and phase III proteins is stimulated 
by increased cellular amounts of environmental 
xenobiotics, which may result in higher protein 
expression and subsequently in lower amounts of 
xenobiotics. It is evident that these transcriptional 
factors are involved in the control of most human drug 
metabolising CYPs.
Polymorphisms of receptors CAR, PXR, and AhR 
have also been described in literature. For example 
more than 10 mutations in the AhR gene have been 
identifi ed to be able to modulate CYP activity (19, 
20).
Of special interest are interaction studies in human 
liver microsomes using CYP- specifi c inhibitors, 
which give important information of the role of CYPs 
in the biotransformation of different xenobiotics 
(21-26). In vitro systems can reliably predict enzyme 
specifi city and drug clearance, provided that the drug 
is not metabolised in phase II reactions. In addition, 
knockout mouse and transgenic models provide many 
advantages in studying physiological and toxicological 
roles of different CYPs.
Herbs with the potential to signifi cantly modulate 
the activity of drug-metabolising enzymes, notably 
CYPs and drug transporter P-glycoprotein, include 
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garlic (Allium sativum), ginkgo (Ginkgo biloba), 
echinacea (Echinacea purpurea), ginseng (Panax 
ginseng), St John’ s wort (Hypericum perforatum), 
kava (Piper methysticum), and grapefruit (Citrus 
paradisi). All of these products can participate in 
pharmacokinetic interactions (27-29).
Cytochrome P450 genes
The nomenclature for cytochrome P450 (CYPs) 
uses designation “CYP” followed by a number 
indicating the gene family (for a gene to be in the 
same family, its aminoacid sequence should be 
identical in over 40 %), followed by a letter indicating 
the subfamily (over 55 % of identical amino acid 
sequence) and the gene number (30). The same gene 
number means that genes have the same function and 
are highly conserved. Human genome sequence has 
revealed about 107 human P450 genes: 59 active and 
about 48 pseudogenes (31). The majority of hepatic 
drug metabolising enzymes are polymorphic. A gene 
is considered to be polymorphic when the frequency of 
a variant allele in normal population is at least 1 %.
Genes encoding xenobiotic metabolism (CYP1-3) 
differ in their characteristics from genes important 
for the metabolism of predominantly endogenous 
compounds (CYP4-CYP51). The fi rst group includes 
a number of pseudogenes, that is, genes encoding 
chemical metabolism that have been inactivated 
as a result of adaptation to the environment. In 
CYP families 1 to 3, the majority of genes are also 
functionally polymorphic, with the exception of 
CYP1A1, CYP2E1, and CYP3A4, which are relatively 
well-conserved. The reason for this conservation 
might be  that these enzymes have some endogenous 
substrates in addition to the exogeneous. Pseudogenes 
are also present in some CYPs involved in endogenous 
metabolism (CYP21P), but there is signifi cantly less 
variability than in CYP families 1 to 3. Inter-ethnic and 
inter-racial differences in frequencies of polymorphic 
gene variants are also worth noting (32).
Genetic polymorphism is an important reason 
for variations in drug response of the human 
body. In terms of drug metabolism, there are four 
specifi c phenotypes that can be determined by either 
Table 1 Participation of various human cytochrome P450 enzymes in the metabolic activation of pre-carcinogenes (9)




Benzanthracene Afl atoxin B1 Benzene Afl atoxin B1
4-Amino-biphenyl Benzo(a)pyrene DEN Chloroform Afl atoxin G1
GluP-1 DMBA IQ DEN 6-Amino-chrysene





















MeIQ  2-amino-3,4 dimethylimidazo(4,5-f)quinoxaline,
MOCA  4,4’-methylene-bis(2-choloroaniline),
NNK  4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone
PhIP  2-amino-1-methyl-6 phenylimidazo(4,5-b)pyridine,
Trp  P-2, 2-aminodipyrido(1,2-a: 3’,2’-d)imidazole
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phenotyping or genotyping: a poor metaboliser 
(PM), intermediate metaboliser (IM), extensive 
metaboliser (EM), and ultrarapid metaboliser 
(UM). Phenotyping involves administration of a 
test drug whose metabolism dependens only on the 
enzyme involved, followed by the estimation of 
the metabolic ratio (MR, defi ned as the ratio of the 
parent/unchanged drug to its metabolite measured in 
serum or urine). Drug concentration is often measured 
using methods like HPLC, GC-MS or LC-MS (33). 
Phenotyping is very useful in pharmacokinetic studies, 
as it reveals the extent of drug-drug interactions or 
impairments in drug biotransformation. On the other 
hand, phenotyping has several disadvantages, which 
include complicated test protocols, risk of adverse 
drug reactions, and the risk of incorrect phenotype 
designation due to coadministration of drugs or 
confounding effects of a disease. Genotyping involves 
identifi cation of defi ned genetic mutations that result 
in specifi c drug metabolism. These mutations can be 
genetic alterations that lead to overexpression (gene 
multiplication), absence of an active protein product 
(null allele), or production of a mutant protein with 
diminished catalytic capacity (inactivating allele). 
Genotyping is predominantly based on polymerase 
chain reaction (PCR) methods. An important 
technological advance in genetic testing is the DNA 
microarray, which allows for simultaneous testing of 
thousands of DNA sequences (34). 
A poor metaboliser lacks active allele and may 
experience more adverse events at usual doses due to 
reduced metabolism and increased drug concentration. 
If individuals lacking the active allele receive a prodrug, 
they may not respond due to a lower-than-expected 
concentration of the active metabolite. Individuals with 
intermediate metabolic phenotype are homozygous for 
two reduced activity alleles or are heterozygous for an 
inactive allele. They may experience some, or a lesser 
degree of the consequences of the poor metaboliser. 
Extensive metaboliser has two fully active alleles 
and shows the expected response to a standard dose. 
Ultraextensive metabolisers are individuals with more 
than two copies of active gene. They may not reach 
therapeutic concentrations at usual, recommended drug 
doses due to increased metabolism. When a prodrug 
is administered, they may experience adverse effects 
due to higher-than-expected concentrations of active 
metabolite.
Adverse drug reactions (ADRs) pose substantial 
diffi culties in drug treatment and drug development. 
It has been estimated that ADRs cause more than 
100,000 deaths a year in the US alone (35), up to 7 % 
of all hospital admissions in the UK, and 13 % of all 
admissions to internal medicine clinics in Sweden 
(36). ADR burden in the US is about US$ 100 billion 
a year (35).
The knowledge that enzyme systems take the 
central role in developing ADRs is crucial for drug 
therapy. About 59 % of drugs cited in ADR studies 
are metabolised by polymorphic phase I enzymes, and 
among those CYPs account for 86 %. By contrast, 
only 20 % of drugs that are non-polymorphic enzyme 
substrates are included in ADR reports (37). Clinically 
the most important polymorphisms are of the CYP2C9, 
CYP2C19, and CYP2D6 genes.
Understanding of the genetics and biology of phase 
I and II enzymes can help to predict a lot of events 
related to the metabolic activation of carcinogens 
and the relative risk for toxic or carcinogenic 
effects of other xenobiotics. Table 3 summarises the 
functional profi le of polymorphic CYPs involved in 
the biotransformation of xenobiotics.
This article has focused on some of phase I CYPs 
participating in the metabolism of xenobiotics.
CYP1A1
CYP1A1 is mainly expressed in extrahepatic 
organs, especially in epithelial tissues. A relevant 
feature of this enzyme is its ability to catalyse 
the first step in the metabolism of polycyclic 
aromatic hydrocarbons (PAHs, also present in 
tobacco smoke), which may lead to a formation of 
electrophilic carcinogenic molecules. CYP1A1 also 
catalyses oxidation of several xenobiotic chemicals 
such as 7-ethoxyresorufi n, theophylline, caffeine, 
7-ethoxycoumarin, and chlorzoxazone, and of 
endogenous chemicals such as 17β-estradiol and 
estrone (38). CYP1A1 polymorphism affects both 
CYP1A1 regulation and structure. Regulation 
begins with the binding between the inducing 
agent (xenobiotic substrate to be metabolised) and 
intracellular arylhydrocarbon receptor (AhR). This 
high-affi nity receptor is associated with high CYP1A1 
inducibility. The AhR complex can also interact 
with the activity of a variety of components of the 
endocrine system (tumour necrosis factor α, epidermal 
growth factor receptor, or glucocorticoid and estrogen 
receptors). There are genetic polymorphisms in the 
AhR gene in humans, and interindividual differences 
in AhR phenotype have been observed (39). About 
one-tenth of the population have the high-affi nity AhR 
phenotype and highly inducible CYP1A1 (40).
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More than 11 alleles of CYP1A1 have been 
identifi ed, (41) of which CYP1A1*2B, *2C, *3, *4, *5, 
*6, *7, *8, *9, *11 show amino acid changes. However, 
it is unclear whether these amino acid changes alter 
catalitic activities in oxidation of xenobiotics, including 
PAHs. There is evidence of race-related differences 
in the genetic polymorphism of CYP1A1(42, 43); 
CYP1A1*2A and CYP1A1*2C variant alleles are 
more frequent in Asian (Japanese) than Caucasian 
populations. CYP1A1*3 allele is specifi c for African 
blacks, and has not been found in either Asian or 
Caucasian populations. This polymorphism has been 
reported to increase the risk for African-Americans 
of adenocarcinoma (44). Other studies do not support 
this fi nding (45). Most investigations on cancer risk 
arising from CYP1A1 polymorphism have studied 
the effects of modifi ed CYP1A1 in association with 
defi cient phase II enzymes (predominantly GST) 
and other gene variants that affect activation and 
detoxification of CYP1A1 substrates (46). GST 
detoxifi es many of activated carcinogens that are 
produced during the Phase I metabolism. There 
are numerous confl icting epidemiological studies 
addressing correlations between cytochrome CYP1A1 
genetic polymorphisms and lung cancer susceptibility, 
with associations plausibly linked to alterations in 
carcinogen bioactivation. Some studies showed that 
a combination between overexpressed CYP1A1 and 
defi cient GST highly increased lung cancer risk after 
exposure to PAHs (47, 48). Moreti at al. (49) published 
results of a cross-sectional study that aimed to evaluate 
whether genetic polymorphisms for CYP1A1, EPHX 
(epoxide hydrolase), and GSTM1 genes that affect 
PAH activation and detoxifi cation might infl uence 
the extent of primary DNA damage in PAH-exposed 
workers. They showed that molecular epidemiology, 
that is cross-sectional study of genotoxicity biomarkers, 
can help identify common genetic risk markers and 
associate effects with measured exposure data. Shah 
et al. (50) reported that lung cancer risk increased 
two to four times in patients carrying the genotype 
combination of CYP1A1*2A and GSTM1 (deletion 
polymorphisms), which suggests that lung cancer 
susceptibility may depend on interactions between 
genes. In the same study, tobacco smoking or chewing 
and alcohol consumption were also found to interact 
with CYP1A1 genotypes in terms of increased risk, 
which further confi rmed a role of gene-environment 
interaction in the development of lung cancer.
Other published data (51) also gave evidence 
of gene-gene interactions which include CYP1A1 in 
lung carcinogenesis. A population-based study (52) 
found that Caucasians but not African Americans 
with IIe/Val (CYP1A1*2C) genotype were at a lower 
risk of developing lung cancer than those with lle/lle 
(*1/*1) genotype, after adjusting for age at diagnosis, 
sex, years of smoking and family history of cancer. 
A recent study (53) pointed to a potential role of 
oestrogen in lung cancer susceptibility. Authors 
evaluated 11 SNPs in genes involved in tobacco and 
oestrogen metabolism (CYP1A1*2A, CYP1A1*2C, 
CYP1B1*3, CYP17, CYP19A1, XRCC1 Gln(399)Arg, 
COMT Val(158)Met, NQO1 Pro(187)Ser, GSTM1, 
GSTT1, and GSTP1 Ile(105)Val. The study included 
504 women aged 18 to 74, diagnosed with non-small 
cell lung cancer (NSCLC) and 527 controls. Lung 
cancer risk associated with individual SNP was 
established for GSTP1 (A allele) and XRCC1 (A/A 
genotype) in white women smokers and for CYP1B1 
(G allele) in black women smokers. White women 
smokers carrying two risk genotypes at the following 
loci - CYP17 and GSTM1, COMT and GSTM1, 
CYP17 and GSTT1, XRCC1 and GSTP1, CYP1B1 and 
XRCC1, and COMT and XRCC1 - were at a higher 
risk of lung cancer than individuals not carrying risk 
alleles at these loci. This suggests that even the most 
parsimonious model of lung cancer risk assessment 
in white smoking women should include age, family 
history of lung cancer, history of chronic lung disease, 
pack-years, BMI, XRCC1 A/A genotype, GSTM1 null, 
and COMT A/G or G/G genotype. These fi ndings also 
support the need for continued study of oestrogen in 
relation to lung cancer risk.
Shi et al. (54) summarised data from 46 studies 
and conducted a meta-analysis of CYP1A1 and 
GSTM1 polymorphisms and lung cancer risk in 
Chinese populations. They confi rmed the association 
between the CYP1A1*2C allele variant and GSTM1 
with increased risk of lung cancer. For the same 
polymorphisms, an eightfold increase in susceptibility 
to lung cancer was demonstrated in a north Indian 
population (55). A Korean group (56) investigated 
the association between CYP1A1*2C, CYP1B1*3, 
GSTP1 Ile105Val, and MPO G-463A polymorphisms 
and lung cancer risk in never-smoking Korean 
women. They found CYP1A1*2C polymorphism 
associated with a signifi cantly lower risk of lung 
adenocarcinoma. However, a combination of risk gene 
variant CYP1B1*3 with CYP1A1*2C was associated 
with a higher risk of lung adenocarcinoma as well 
as of overall lung cancer. Variability assessment 
of tobacco metabolism, oestrogen metabolism, and 
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DNA repair pathways could be useful in developing 
more predictive models for individual cancer risk in 
connection with CYP1A1 polimorphism.
Other published data (57) suggest that CYP1A1 
polymorphisms could be useful predictors of breast 
cancer risk as well as of some tumour characteristics. 
Variant allele 6235C carriers at the 3’ noncoding 
region, and variant allele 462Val carriers at the 
codon 462 polymorphism showed a significantly 
reduced breast cancer risk than noncarriers. Another 
study found that carriers of CYP19 (TTTA)7(-
3bp) and CYP1A1 C6235T polymorphisms had a 
signifi cantly increased risk of ER-positive breast 
cancers, which could be a useful information in 
Table 2 General properties of human cytochrome P450 enzymes in families 1-3 (9)





CYP1A1 Ethoxyresorufi nO-deethylation Pre-carcinogens, 
PAHs
Extrahepatic Inducible by PAHs, 
endogenous role in cell 
growth




Liver Inducible by PAHs and 
some drugs
CYP1B1 Estradiol-4-hydroxylation DMBA, 
oestradiol
Extrahepatic Inducible by PAHs, high 
affi nity for some PAHs
CYP2A6 Coumarin 7-hydroxylation Nicotine Liver The major nicotine oxidase, 
active on some drugs and 
carcinogens
CYP2A13 Coumarin 7-hydroxylation Olfactory 
mucosa





losartan hydroxylation, S-warfarin 
7-hydroxylation
Many drugs Liver Very important for drug 
metabolism






Many drugs Liver Highly polymorphic, 







Many drugs Liver Very important for drug 
metabolism
CYP2E1 Chlorzoxazone 6-hydroxylation Solvents, 
many drugs, 
precarcinogens




CYP2J2 Arachidonic acid hydroxylation Fatty acids Extrahepatic
CYP2R1 Vitamin D25 hydroxylase Vitamin D Extrahepatic The function recently 
revealed
CYP2S1 Trans-retinol oxidation Small aromatic 
hydrocarbons











Liver, intestine The most important P450 in 
drug metabolism
CYP3A5 Same as CYP3A4 Similar as 
CYP3A4
Liver, intestine Expressed in some 
individuals
CYP3A7 Same as CYP3A4 Similar as 
CYP3A4
Liver, intestine Mainly expressed in fetal 
liver
CYP3A43 Not known Not known Liver Tiny expression, active?
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screening for chemoprevention with tamoxifen 
(58). Some studies (59) confi rmed earlier reports 
that CYP1A1*2C-containing genotypes modified 
the association between PCB exposure and risk of 
breast cancer. They presented additional evidence 
suggesting that CYP1A1*3-containing genotypes 
modifi ed the effects of PCB exposure among African 
American women. A Russian group (60) estimated the 
frequency of CYP1A1, CYP1A2, CYP1B1, CYP19, 
and SULT1A1 allele variants in a female population 
of the Novosibirsk district and their associations 
with higher risk of breast (BC), ovarian (OC), 
and endometrial (EC) cancers. It found signifi cant 
differences in allele distributions for CYP1A1*2A 
polymorphism between patients with BC and controls. 
Furthermore, signifi cant differences were found in 
the allele and genotype distributions for CYP1A2*1F 
polymorphism between patients with BC and OC. 
The frequency of a mutant CYP19 heterozygote 
genotype C/T was higher in patients with OC and 
EC than in healthy women. These results support the 
hypothesis that the susceptibility gene of oestrogen-
metabolising enzymes may involve different risk of 
hormone-dependent cancers in women. Report on the 
association between a combination of CYP1A1 and 
SULT gene polymorphisms and endometrial cancer 
suggests that decreased variant allele CYP1A1*2A 
and increased variants of SULT1A1(Arg213His, 
14A/G, 85C/T) and SULT1E1-64G/A may be risk 
factors for endometrial cancer in Caucasians (61). 
Oestrogens have also been proposed to act as tumour 
promoters and inducers of hepatocarcinogenesis. We 
observed a signifi cant association between the risk 
of hepatocellular carcinoma and the polymorphisms 
of the oestrogen receptor alpha (ESR1) gene. A 
Chinese group (62) confi rmed the association between 
hepatocellular carcinoma (HCC) and four variants of 
CYP1A1 in a study that included 1006 pathologically 
confi rmed HCC patients and 1015 cancer-free controls 
from Han population. Another Chinese study (63) 
could not confi rm these results and concluded after 
stratification by common confounding factors of 
Table 3 Functional importance of polymorphism in human P450 enzymes involved in xenobiotic metabolism
Enzyme Substrate Frequency of 
variant alleles
Functional effects Clinical 
effects
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hepatocellular carcinoma, that the polymorphisms in 
enzymes involved in the biogenesis (CYP17,CYP19), 
bioavailability (CYP1A1, CYP1B1), and degradation 
(catechol-O-methyltransferase) of oestrogens were not 
associated with the risk of hepatocellular carcinoma. 
Furthermore, no signs of gene-gene interactions were 
observed for any of the combinations of the seven 
polymorphisms. Recent fi ndings (64) suggest that 
common variants in hormone-related genes contribute 
to the risk of biliary tract cancers and stones, possibly 
by modulating hormone metabolism. Genotyping 
18 SNPs in 9 genes involved in steroid hormone 
biosynthesis, metabolism, and transport revealed 
that CYP1A1 IVS1 + 606 (rs2606345) T allele had a 
possible impact on gallbladder and bile duct cancers, 
while the CYP1A1 Ex7 + 131 (rs1048943) G allele 
was associated with ampulla of Vater cancer.
Other studies partly support that polymorphic 
variations in CYP1A1 (*2A, *2C, *4) may play a role 
in colorectal cancer (65-67).
CYP1A2
CYP1A2 is mainly expressed in the liver. The level 
of CYP1A2 protein is 10 % to 15 % of total P450 in 
human adult liver. Expression levels vary about 40 
times between individuals.
CYP1A2 catalyses metabolic activation of a 
variety of aryl- and heterocyclic amines such as 2-
aminoanthracene and 2-acetylaminofl uorene (Tables 
1 and 2). CYP1A2 catalyses the activation of PAH-
diols to reactive metabolites at much slower rates than 
CYP1A1 and 1B1. CYP1A2 oxidizes other xenobiotic 
chemicals including acetaminophen, antipyrine, 
caffeine, 7- ethoxyresorufi n, lidocaine, phenacetin, 
theophylline, and R-warfarin. More than 16 CYP1A2 
polymorphic alleles have been identifi ed (41). Alleles 
CYP1A2*2-*16 show amino acid changes (68, 69). 
In vitro studies revealed that the CYP1A2*11 allele 
variant decreases 7-ethoxyresorufi n O-deethylation 
activity (70) The CYP1A2*7 allele contains a splicing 
defect (G3534A), which is responsible for a decrease 
in clozapine (an atypical antipsychotic) concentrations 
in vivo (69). CYP1A2*1F (-163C>A) is associated 
with a high inducibility of CYP1A2 in smokers. Some 
reports (71) described cases where smoking patients 
did not respond to clozapine treatment and had low 
drug plasma levels at normal doses. A discontinuation 
in smoking might lead to elevated clozapine plasma 
concentrations and severe side effects (72). As 
schizophrenic patients have a high frequency of 
smokers and a high frequency of the -163C>A 
polymorphism, CYP1A2 genotyping could have 
important clinical implications. Reports described 
patients with CYP1A2*1F CC genotype treated for 
rheumatoid arthritis, who had a 9.7 times higher risk 
of overall lefl unomide-induced toxicity than did the 
carriers of the CYP1A2*1F A allele (73). It is not fully 
understood whether CYP1A2 gene polymorphism 
relates to cancer susceptibility in humans. Some 
findings indicate that the association between 
cigarette smoking and colorectal carcinogenesis can 
be modifi ed by the CYP1A2 genotype (74). Signifi cant 
associations were found between the CYP1A2*1F and 
the risk of colorectal adenomas (75). Aromatic amines, 
N-nitroso compounds and heterocyclic amines are 
suspected human pancreatic carcinogens. Study (76) 
results of association between the interaction of the 
CYP1A2, SULT1A1 and NAT gene polymorphisms 
with smoking and dietary mutagen intake in modifying 
pancreatic cancer risk revealed that CYP1A2 and 
NAT1 genotypes exhibited signifi cant interactions 
with heavy smoking in women, but not in men. 
These data indicate a sex-specifi c susceptibility to 
tobacco carcinogen and dietary mutagen exposure in 
pancreatic cancer. They are in agreement with other 
published data (77). Some reports suggest that the 
CYP1A2*1F polymorphism has an important role 
in lung carcinogenesis, especially in squamous cell 
carcinoma among smokers (78). Ninety-fi ve percent 
of caffeine is metabolised by cytochrome CYP1A2, 
and caffeine induce the enzyme. A common A to C 
polymorphism at position 163 in the CYP1A2 gene has 
been associated with decreased enzyme inducibility 
and enzymatic activity, resulting in the slower 
metabolism of caffeine (79-81). Some studies reported 
that among breast cancer susceptibility gene (BRCA1) 
mutation carriers, the consumption of caffeinated 
coffee was associated with a signifi cant reduction in 
breast cancer risk (82). Another study indicated that 
CYP1A2 genotype did not affect breast cancer risk. 
However, among women with at least one variant 
C (AC or CC, at position 163), those who consumed 
coffee had a 64 % lower breast cancer risk than women 
who never consumed coffee (83).
Increased risk of myocardial infarction with 
increasing coffee consumption has been reported 
among carriers of the variant C of the CYP1A2 gene 
(84). The authors attributed this to the prolonged 
presence of caffeine in the circulation among the slow 
metabolisers due to lower enzyme inducibility.
CYP1B1
CYP1B1 is expressed in the endoplasmatic 
reticulum of extrahepatic organs, predominantly in 
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the steroidogenic tissues of the uterus, breast, ovary, 
testis, prostate and adrenal gland. It is also expressed 
in many other extrahepatic tissues including the 
lung, kidney, thymus, spleen, brain, heart, colon and 
intestine. Higher levels are found in a wide range of 
human cancers including cancers of the skin, brain, 
testis (85) and breast (86). CYP1B1 converts oestrogen 
to 4-hydroxylated metabolites (87) that may initiate 
breast cancer in humans (88). The enzyme also plays 
an important role in activating diverse procarcinogens 
including PAHs, aryl and heterocyclic amines and 
nitroarenes to reactive metabolites that cause DNA 
damage (Table 1) (89, 90).
More than 26 polymorphisms of CYP1B1 have 
been identifi ed in humans; 19 of these variants show 
amino acid changes (41). The null allele of CYP1B1 
has been associated with hereditary glaucoma (91). 
The role of allelic variants in enzyme activity and 
their association with different forms of cancers have 
not yet been fully understood, and literature reports 
conflicting results. The complexity of haplotype 
distribution and relatively small functional effects 
indicate that CYP1B1 polymorphism alone does not 
signifi cantly affect cancer risk associated with either 
lifelong smoking or lifelong exposure to polyaromatic 
hydrocarbons or oestradiol. New data suggest that 
combined polymorphisms in the CYP1B1 and phase 
II metabolic enzymes (GST, NAT), which are 
responsible for metabolic activation/detoxifi cation 
of oestrogen and environmental carcinogens, could 
be susceptibility factors associated with cancer risk. 
CYP1B1 and GST polymorphisms in some studies 
were found significant in the aetiology of breast 
cancer, especially in women before the age of 60 
(92). Stratified analyses demonstrated significant 
interactions in younger Caucasian women with 
the 119SS variant of the CYP1B1*2 allele, (A119S 
aminoacid change), and in younger African-American 
women with the GSTT1 null allele genotype. This 
trend was also found in Caucasian women with 
a history of smoking and at least one 114-valine 
allele at GSTP1. In Caucasian women, combined 
genotype variants GSTP1- 105IV/VV(Ile105Val) 
and CYP1B1*2, 119AA resulted in a nearly twofold 
increase in risk, and the combination of three genotype 
variants GSTP1 105IV/VV, CYP1B1 119AS/SS and 
GSTT1 null resulted in an almost fourfold increase 
in risk. Data also reveal that polymorphisms in phase 
I (CYP1B1) and phase II (GSTM1, GSTT1, GSTP1) 
enzymes may enhance the occurrence of mutations 
at critical tumour suppressor genes, such as p53 
(93). Since CYP1B1 belongs to a multitude of genes 
regulated by the oestrogen receptor alpha (ERalpha) 
expression, it is of interest to know whether CYP1B1 
polymorphisms have an impact on the ERalpha status 
of breast cancer. Some authors observed a signifi cant 
association between the homozygous variant CYP1B1-
1358GG (increase CYP1B1 enzymatic activity) 
and negative ERalpha status. They also observed 
an association between CYP1B1 1358GG and 
progesterone receptor negative status (p=0.015) (94). 
The association between the cytochrome CYP1B1*3 
allele and breast cancer was assessed (95) through a 
meta-analysis of all published case-control studies and 
a pooled analysis of both published and unpublished 
case-control studies from the Genetic Susceptibility 
to Environmental Carcinogens (GSEC) database. No 
association between CYP1B1*3 and breast cancer 
was observed in Asians, an inverse association was 
observed in populations of mixed/African origin, and 
the pooled analysis suggested a possible association 
in Caucasians, with effect modifi cation across age 
categories. Authors suggested that the observed effect 
of age on the association in Caucasians indicates a 











celecoxib, diclofenac, ibuprofen, indomethacin, naproxen, tenoxicam
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need for further investigation of the role of CYP1B1*3 
in oestrogen metabolism according to age, ethnicity, 
and menopausal status.
Other studies (96) provided some support for 
polymorphic variation in CYP1A2 and CYP1B1 
playing a role in colorectal cancer susceptibility. 
These authors also pointed out the importance of 
gene-environment interactions to be included in 
such studies to obtain reliable information about 
carcinogen exposure and diet. There are reports (97) 
on signifi cant differences in the distribution of variant 
alleles CYP1B1*2 between patients with head and 
neck squamos cell carcinoma (HNSCC) and controls. 
Furthermore, data indicated a several-fold increase in 
the risk of HNSCC in patients with the variant alleles 
CYP1B1*2 and CYP1B1*3 who either smoked or 
chewed tobacco or drank alcohol. Another recent study 
(98) has also underlined the relevance of the CYP1B1 
genotypes combined with exposure to tobacco smoke 
for HNSCC susceptibility. It investigated individual 
genetic predisposition to HNSCC associated with 
enzymes of xenobiotic metabolism and repair enzymes 
affected by tobacco smoke and included 22 sequence 
variations in CYP1A1, CYP1B1, CYP2E1, ERCC2/
XPD, GSTM1, GSTP1, GSTT1, NAT2, NQO1, and 
XRCC1. To assess relevant main and interactive 
effects of polymorphic genes on the susceptibility 
to HNSCC they used statistical models such as log 
regression and a Bayesian version of log regression. 
In subgroup analysis of nonsmokers, the main effects 
in ERCC2 (Lys751Gln) C/C genotype and combined 
ERCC2 (Arg156Arg) C/A and A/A genotypes were 
predominant. When stratifying for smokers, the data 
revealed main effects on CYP1B1*3/*3 genotypes, 
followed by CYP1B1*1/*3, and CYP2E1*7B. When 
fi tting log regression models including relevant main 
effects and interactions in smokers, the authors found 
relevant association beetween genotypes containing 
CYP1B1*3 or CYP2E1*7B and HNSCC as well as 
between CYP1B1*3/*3 or GSTM1 null/null genotype 
and HNSCC.
Another group (99) have similar approach to 
determine genetic interactions in HNSCC. They 
used log regression, which is well suited for SNPs, 
and Bayesian generalisation, which allows for 
incorporating additional expert knowledge. These 
methods determined several important interactions 
such as association between CYP1B1, tobacco 
smoke, and p53 mutations and interactions between 
CYP1B1 and glutathione S-transferases in smokers, 
which included a three-way interaction between 
CYP1B1, CYP2E1, and GSTP1. An association study 
(100) based on 1,023 patients and 1,121 controls, 
investigated the infl uence of environmental factors 
combinated with six SNPs located in CYP1A2, 
CYP2E1, CYP1B1, and CYP2C9 on the risk of 
sporadic colorectal cancers (CRC). Whereas separate 
analyses of the SNPs showed no effect on CRC risk, 
three allelic variant combinations were found to be 
associated with a signifi cant increase in CRC risk in 
interaction with an excessive red meat consumption. 
One of these three predisposing combinations was also 
shown to interact positively with obesity. Some study 
results (101) suggest that genetic polymorphisms 
in CYP1B1 may modify the risk of prostate cancer. 
Another report (102) on the association between the 
CYP1B1*3 allele and survival in patients with prostate 
cancer receiving docetaxel has provided evidence that 
CYP1B1*3 may be an important marker for estimating 
docetaxel effi cacy, explaining this by CYP1B1*3 
genotype-dependent oestrogen metabolism.
 It appears that CYP1B1 along with Phase 
II enzymes play a key role in the activation of 
carcinogens at several organ targets, with a complex 
gene-environment interactions. 
CYP2C9
CYP2C9 is predominantly expressed in the liver, 
representing about 20 % of the hepatic CYP content. 
It metabolises about 15 % of drugs in current 
use, some of which are of substantial clinical 
importance such as angiotensin-2 antagonists, 
nonsteroidal antiinfl ammatory drugs (NSAIDs), 
oral antidiabetics, antiepileptics, oral anticoagulants, 
psychotropic drugs, and alkylating anticancer 
prodrugs (Table 4) (103, 104). In addition, CYP2C9 
metabolises endogenous substrates arachidonic 
and linolenic acid (105). CYP2C9 also mediates 
3-hydroxylation of B[a]P and metabolic activation 
of several PAH-diols to active metabolites at much 
slower rates than those by CYP1 enzymes (106). 
Genetic polymorphisms of CYP2C9 include more than 
34 alleles (41). Alleles CYP2C9*2, *3, *4,*5, and *30 
have aminoacid replacement, and have been reported 
to reduce in vitro (107,108) and/or in vivo catalityc 
activities (108, 109, 110).
There is a large interindividual variation in CYP2C9 
activity resulting in variations in drug response and 
adverse effects. In Caucasian population, poor 
metabolisers make 3 % to 5 %. The most frequent 
variants are the CYP2C9*2 and CYP2C9*3 alleles. 
Of special interest are drug substrates with a narrow 
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therapeutic index such as S-warfarin, tolbutamide 
and phenytoin, where impaired CYP2C9 metabolic 
activity might cause diffi culties in dose adjustment 
as well as toxicity (111, 112). Patients with the 
CYP2C9*2 and CYP2C9*3 alleles have lower mean 
daily warfarin doses and a greater risk of bleeding 
(113). CYP2C9 polymorphisms can also be associated 
with an increased rate of NSAID-induced adverse 
events (114). NSAIDs have been shown to effectively 
prevent colorectal neoplasia. Polymorphisms in 
NSAID targets or metabolising enzymes may affect 
NSAID efficacy or toxicity (115). Some authors 
(116) reported enhanced chemopreventive activity 
of ibuprofen against colorectal cancer by slower-
metabolising CYP2C9 variants (*2/*3). Others 
(117) investigated the association of elimination rate 
and clinical outcome of anticancer agent indisulam 
with CYP2C9/CYP2C19 gene variants. CYP2C9*3, 
CYP2C19*2, and CYP2C19*3 polymorphisms 
resulted in a reduced elimination rate of indisulam. 
These mutant alleles signifi cantly increase the risk of 
severe neutropenia, and dose reductions of 50 mg m-2 
to 100 mg m-2 per mutated allele may be required to 
normalise the risk.
Beside genetic polymorphisms, interindividual 
variability in CYP2C9 enzyme activity can also be 
changed by environmental factors; it is induced by 
prototypical CAR, PXR, and GR ligands through 
different elements in the promoter region or inhibited 
by oral contraceptives, as shown in a study on healthy 
women (118). The observed intraethnic variability 
reinforces the need for proper selection of control 
subjects and argues against the use of surrogate control 
groups for studies on the association between CYP2C9 
alleles and adverse drug reactions or spontaneous 
diseases (119).
CYP2C19
When it comes to drug metabolysm catalysed by 
CYP2C19, two to fi ve percent of Caucasians and about 
20 % of Asians are poor metabolisers (PMs) (120). 
Currently, there are over 25 different alleles of the 
CYP2C19 gene (2C19*1-*25), of which CYP2C19*2-
*8 code for inactive versions of the enzyme and 
CYP2C19*17 for increased enzyme activity (41). In 
Asians, alleles CYP2C19*2 and *3 together account 
for 100 % of the defective alleles. In the Caucasian 
population 85 % of PMs are homozygous for 
CYP2C19*2. CYP2C19*3 to *25 alleles are extremely 
rare in Caucasians. The CYP2C19 genotype can 
seriously affect the success of drug therapy. In PMs, 
proton pump inhibitor omeprazole has a considerably 
prolonged half-life. Patients heterozygous for a 
defective CYP2C19 allele displayed an improved 
cure rate for Helicobacter pylori infections during 
concomitant omeprazole and amoxicillin treatment. 
Patients with two defective alleles had a cure rate 
of 100 % (121). Other important clinically used 
drugs that are affected by CYP2C19 polymorphisms 
are the tricyclic antidepressants amitriptyline and 
clomipramine, selective serotonin reuptake inhibitors 
sertraline and citalopram, the monoamine oxidase 
inhibitor moclobemide, barbiturates, the anxiolytic 
diazepam and the antimalarial drug proguanil (Table 
5) (122). The CYP2C19 phenotype is measured 
through oral administration of S-mephenytoin. In 
individuals with the extensive metabolic phenotype, 
S-mephenytoin is quickly conjugated and excreted 
in the urine. In contrast, in PMs, virtually no 
hydroxylation occurs. A recent study found that 
patients (n=166) on escitalopram therapy, carrying the 
CYP2C19*17 allele (UM phenotype) exhibited 42 % 
lower plasma concentrations than those homozygous 
for CYP2C19*1 and underlined the necessity of dose 
adjustment (123). The rate of nelfi navir (for HIV 
treatment) biotransformation to M8 was reduced by 
50 % in patients with the CYP2C19*1/*2 or *2/*2 
genotype compared to those with the *1/*1 genotype, 
with consequences of modifi ed short-term effi cacy 
and toxicity and fi nal virological response (124). 
Some reports documented that the CYP2C19*2 
loss-of-function polymorphism was associated with 
an increased treatment-related mortality (TRM) in 
patients undergoing allogenic transplantation (125). 
Patients genotyped as PMs had a signifi cantly higher 
rate of hepato- and nephrotoxicities than intermediate 
or extensive metabolisers. Multivariate analysis 
including all potential factors that might infl uence 
TRM have confi rmed that the CYP2C19 genotype is 
an independent factor which considerably infl uences 
TRM. These results suggest that genotyping for 
CYP2C19 can help to identify patients with a higher 
risk of TRM.
CYP2D6
CYP2D6 constitutes a surprisingly important 
enzyme for drug metabolism, despite its low hepatic 
content (about 2 %). Its polymorphisms are of the 
greatest importance for drug metabolism of all phase I 
and II metabolising enzymes. There are more than 80 
different allelic variants, and about 25 % of all drugs 
on the market are metabolised by this enzyme (126). 
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The most important substrates of CYP2D6 (Table 
6) are antidepressants, neuroleptics, antiarrhytmics, 
analgesics, antiemetics, and anticancer drugs (127, 
128). The enzyme also appears to be one of the most 
important polymorphic drug metabolizing enzymes in 
causing adverse drug reactions (129). In addition, the 
enzyme utilises amines and steroids as endogenous 
substrates (5-methoxyindolethylamine and 5-
methoxytryptamine) (130). Besides, it may have a 
major role in the metabolism of food constituents, 
alkaloids in particular (131). CYP2D6 is the only 
non-inducible drug metabolizing CYP, and therefore, 
genetic variation contributes largely to interindividual 
variation in enzyme activity. Different functional 
CYP2D6 gene variants have been described which 
can be classifi ed in categories according to whether 
they abolish, decrease, leave normal, increase, or 
qualitatively alter catalytic activity. The distribution of 
the most common variant alleles among ethnic groups 
and all variant alleles are presented at the home page 
of the human CYP allele nomenclature committee 
(41). The most important variants are CYP2D6*2, 
CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, 
CYP2D6*10, CYP2D6*17, and CYP2D6*41. 
There are four polymorphism-related phenotypes; 
poor (PM), intermediate (IM), extensive (EM), or 
ultrarapid metabolisers (UM). It is plausible that 
the UM genotype (CYP2D6*2xN-duplications), 
with more than one active gene on one allele, is 
the outcome of selective diet in certain North and 
East African populations (132). In the Ethiopian 
and Algerian population the prevalence of UMs is 
29 % (133-135). 20 % of the population in Oceania 
are also UMs. However, the duplication event in the 
Oceania population appears to be of another origin 
since the allele found is CYP2D6*1Xn, and has most 
probably evolved independently from the duplication 
in the African population. The UM phenotype makes 
1 % to 10 % of the European population and the PM 
phenotype 3 % to 10 % (136-139).
New variants of the CYP2D6 gene are continuously 
added to the CYP allele Web page (41). Genotyping 
for 12 SNPs representing 20 different haplotypes 
would predict the real phenotype with about 90 % to 
95 % accuracy (140). Phenotyping with a probe drug 
like dextromethorphan might provide an even more 
accurate estimate (141).
CYP2D6 polymorphism signifi cantly affects the 
pharmacokinetics of about 50 % of drugs in clinical use 
(Table 6). The consequences at normal drug doses can 
be either adverse drug reactions (142, 143) or no drug 
response (144). CYP2D6 polymorphism can affect the 
effi cacy and cost of drug treatment. Predictive CYP2D6 
genotyping is estimated to be benefi cial for treatment of 
about 30 % to 50 % of CYP2D6 drug substrates (145). 
The CYP2D6 genotype has been shown to successfully 
predict the clearance of antidepressants desipramine, 
fl uvoxamine, mexiletine, mianserin, nortryptiline, and 
paroxetine as well as the clearance of the neuroleptics 
perphenazine and zuclopenthixol and the competitive 
muscarinic receptor antagonist tolterodine (146). A lack 
of CYP2D6 enzyme results in reduced effectiveness 
of drug therapy in instances where prodrugs requiring 
activation by CYP2D6 are used. This is seen for the 
analgesic effect of tramadol and codeine. Tamoxifen 
is metabolised into its active metabolite endoxifen 
by N-demethylation and 4-hydroxylation, reactions 
that are catalysed by CYP2D6. Lower therapeutic 
effect has been observed in PMs for CYP2D6, and 
predictive pheno/genotyping is advised before entering 
the treatment (147). When a prodrug like codeine is 
administered to UMs they may suffer of adverse effects 
due to higher-than-expected concentrations of active 
metabolite morphine (148, 149). Mutations in CYP2D6 
gene can also alter substrate specifi city (150).
CYP2E1
In the CYP2E locus only one gene has been 
described in humans. CYP2E1 is expressed in the 
liver with the highest concentration in the centrilobular 
region. This enzyme is reasonably conserved, most 
likely due to important endogenous roles. The 
endogenous regulation of CYP2E1 is similar to that of 
other gluconeogenetic enzymes; the enzyme expression 
Table 5 Important drugs which are substrates of enzyme CYP2C19
Drug groups Drugs
Anticonvulsants barbiturates, phenytoin, valproates
Proton pump inhibitors omeprazole, lansoprazole, pantoprazole
Psychotropic drugs diazepam, imipramine, clomipramine, sertraline, citalopram, moclobemide
Other proguanil, propranolol, ritonavir, tolbutamide
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is repressed during normal diet and increased during 
starvation and diabetes. Its physiological substrates 
seem to be gluconeogenetic precursors acetone and 
acetol and fatty acids. A study in rats (151) showed 
increased CYP2E1 either at transcriptional or post-
transcriptional level in chemically induced diabetes 
and starvation.
The expression of CYP2E1 is also regulated by 
different cytokines. Similar to CYP1A2, CYP2C, 
and CYP3A, the level of CYP2E1 is decreased by 
IL-1, IL-6, and TNF-α in primary culture of human 
hepatocytes (152). By contrast, IL-4 induces the 
expression of the enzyme. CYP2E1 has a very broad 
substrate specifi city. More than 70 different chemicals 
with diverse structures are metabolised by CYP2E1 
(Tables 1 and 2). Most of these substrates are small 
and hydrophobic. They include alcohols/ketones/
aldehydes, aromatic compounds, halogenated alkanes 
or alkenes, anaesthetics, drugs, and premutagens 
such nitrosamines (found in cigarette smoke) and azo 
carcinogens (153-156). Many of the CYP2E1 substrates 
are also inducers of the enzyme. Commonly used 
inducers in experimental animals are ethanol, acetone, 
isoniazid, pyridine, and pyrazole. CYP2E1 activity in 
liver microsomes and in vivo is most often measured 
using the chlorzoxazone 6-hydroxylation method. 
Although the frequency of variant alleles is high, 
their functional signifi cance is not clear, most likely 
due to a high endogenous importance of this enzyme 
in gluconeogenesis during severe fasting/starvation. 
Some investigations suggest that the CYP2E1*5B 
variant increases the susceptibility to colorectal cancer 
(157). In general, gene-environment interactions 
between CYP2E1 polymorphism and smoking or 
alcohol drinking have been associated with the risk of 
colorectal neoplasia. Vinyl chloride (VC) is a human 
carcinogen known to be metabolised by CYP2E1 into 
reactive intermediates that can cause oncogene and 
tumour suppressor gene mutations, and which are 
further metabolised by acetaldehyde dehydrogenase 
(ALDH2) and glutathione-S-transferases to non-
mutagenic end-products. Schindler et al. (158) have 
found that the presence of the CYP2E1*5B allele 
variant was signifi cantly associated with the either 
or both mutant biomarkers (ras-p21 and p53), even 
after controlling for potential confounders, including 
cumulative VC exposure. The effects of *5B allele 
and VC exposure were approximately additive. 
These results also suggest possible gene-environment 
interactions between polymorphisms in the VC 
metabolic pathway and VC exposure that could 
contribute to variable susceptibility to the mutagenic 
effects of VC in exposed populations. Other data 
(159) also suggest that genetic polymorphism in 
CYP2E1 may be associated for individual differences 
in susceptibility to liver fi brosis with regard to chronic 
vinyl chloride monomer (VCM) exposure. Analysis 
of metabolising enzymes might be useful in the risk 
assessment of liver damage in workers occupationally 
exposed to VCM.
Some published data (160) suggest that the 
genotypes of CYP2E1 and of DNA repair genes 
XRCC1 194 (X-ray repair cross-complementing 
group ) and XPD 751 (xeroderma pigmentosum 
complementary group D) are associated with the level 
of DNA damage, and that they may contribute to 
variable sensitivity to DNA damage induced by VCM 
at the workplace. The CYP2E*5B and NAT2 variants 
(NAT2*4/*7, NAT2*5/*6, NAT2*5/*7, NAT2*6/*6 
and NAT2*6/*7 genotypes) were associated with 
chronic obstructive pulmonary disease (161). A group 
of Norwegian scientists (162) in their comprehensive 
study of 105 SNPs in 31 xenobiotic-metabolising 
enzyme genes found strong associations with the 
risk of NSCLC. Results indicated that several SNPs 
in phase I genes CYP1B1, CYP2D6, CYP2E1, and 
CYP3A4 were associated with the risk of NSCLC. 
Moreover, signifi cant associations were also found 
Table 6 Important drugs which are substrates of enzyme CYP2D6 
Drug groups Drugs
Analgesics
codeine, dextromethorphan, fentanyl, hydrocodon, meperidine, methadone, morphine, 
oxycodone, tramadol
Antiarrhythmics amiodarone, aimaline, fl ecainide, lidocaine, mexiletin, propafenone
b-Adrenoceptor 
antagonists
alprenolol, bisoprolol, bufuralol, carvedilol, labetalol, metoprolol, pindolol, propranolol, 
timolol
Psychotropic drugs
amphetamine, amitriptyline, fl uoxetine, fl uvoxamine, haloperidol, imipramine, 
clomipramine, chlorpromazine, clozapine, maprotiline, paroxetine, risperidone, 
thioridazin, trazodone, venlafaxin, zuclopenthixol
Other guanoxane, captopril, tamoxifen, trimetoprim
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with multiple SNPs in phase II genes ALDH2, COMT, 
EPHX1, SOD2, NAT1, NAT2, GSTM3, GSTP1, 
GSTT2, and MPO.
CYP3A4/5
CYP3A4 is the most abundant P450 enzyme in 
the human liver (about 30 % of total P450). CYP3A 
enzymes facilitate the metabolism of a wide range of 
structurally different xenobiotics and of 50 % of all 
clinically used drugs (Table 7) (163, 164). In addition, 
they have a key role in the metabolism of endogenous 
substrates such as retinoic and bile acids and steroid 
hormones such as testosterone and oestrogen 
(127, 165). CYP3A4 is also very important for the 
metabolism/activation of dietary and environmental 
chemicals such as PAH-diols, mycotoxins, afl atoxins 
B1, G1, and sterigmatocystin, pesticides, fl avonoids, 
and a number of food additives (166-168). Catalytic 
activity of CYP3A4 in PAH activation is lower 
than of the CYP1 family enzymes. There are four 
CYP3A human genes, CYP3A4, CYP3A5, CYP3A7, 
and CYP3A43, located at chromosome 7q21-q22.1 
(169).
Clinically relevant CYP3A enzymes, CYP3A4, 
CYP3A5 and CYP3A7, have similar substrate 
specifi cities and are mostly expressed in the liver. 
CYP3A4 and CYP3A7 show an opposite expression 
pattern during development (170). CYP3A7 is 
predominantly expressed in the foetal liver and is 
present up to 6 months of postnatal age, although 
this enzyme can be found in some adult livers and in 
other organs (171). CYP3A4 is the major cytochrome 
P450 isoform present in adult liver. CYP3A5 content 
is constant at all developmental stages, regardless 
of polymorphism. In the foetus, CYP3A7 plays an 
important role in the metabolism of endogenous 
substrates, such as key steroids and retinoic acid, 
and also in the metabolism of xenobiotics reaching 
the foetus from maternal circulation. Interindividual 
variation in CYP3A7 expression could therefore result 
in interindividual differences in embryotoxicity and 
teratogenicity of different substances (172, 173).
CYP3A4 can be inhibited by a number of drugs 
and chemicals. These include azole antifungal agents 
such as ketoconazole, macrolide antibiotics such 
as troleandomycin, HIV protease inhibitors such as 
saquinavir, antidepressants such as fl uoxetine, and 
furanocoumarin, 6’,7’-dihydroxybergamottin found 
in grapefruit juice (174-176). CYP3A4 enzyme is also 
highly inducible by many drugs and dietary chemicals. 
Drug inducers include the macrolide antibiotic 
rifampicin, anticonvulsants such as carbamazepine, 
and glucocorticoids. Components of St John’s wort 
(Hypericum perforatum), hyperforin in particular, are 
potent inducers of CYP3A4 (177). All of them are 
importan for interactions during pharmacotherapy. 
Statins (antilipemic drugs) are mainly metabolised by 
CYP3A4, except fl uvastatin, which is metabolised by 
CYP2C9 and pravastatin, which is largely excreted 
unchanged. Myopathy is a serious adverse effect of 
statins. Concurrent use of statins and fi brates, seems 
to particularly increase the risk of muscular toxicity 
(178).
Coadministration with rifampicin, phenytoin, or 
carbamazepine may reduce plasma AUCs to less than 
half for a broad range of CYP3A4 drug substrates 
(179). A combination of a powerful inhibitor of 
CYP3A4 and a drug dependent on CYP3A4 for 
its metabolism may increase plasma levels of the 
substrate as much as 10 to 20 times and lead to adverse 
drug reactions and toxic effects. Correspondingly, a 
combination with an inducer may decrease plasma 
levels of the substrate to only 5 % to 10 % of its 
original concentration, leading to therapeutic failure 
(180). There is large interindividual variability in 
hepatic CYP3A4 expression (181). CYP3A4 is 
also highly expressed in the intestine (182). The 
enzyme has a substrate specifi city and inducibility 
that is similar to the drug transporter P-glikoprotein 
(P-gp) encoded by the multi-drug resistant/ATP 
binding cassette (MDR1/ABCB1) gene (183, 184). 
Both genes are on the same position on chromosome 
7q21.1 and apparently use similar DR4 regulatory 
elements binding PXR (185, 186). The broad substrate 
specifi city, the capacity of CYP3A4 to metabolise 
xenobiotics, and co-regulation with P-gp makes 
these two components perhaps the most important 
complex for the elimination of xenobiotics from 
the body (187-190). Probe substrates for CYP3A4 
include midazolam (1’ hydroxylation), erythromycin 
(N-demethylation), cortisol (6β-hydroxylation in vivo) 
and testosterone (6β-hydroxylation in vitro). Although 
there is a considerable interindividual variation in 
the expression and activity of CYP3A4, genetic 
polymorphisms alone do not provide a satisfactory 
explaination (191). More than 20 mutations in the 
CYP3A4 gene have been identifi ed, but were of unclear 
importance (41). Different CYP3A4 variant proteins 
have been described, with decreased (*8,*11,*13*17), 
none (*20), or increased activity (*18A) allele in vitro. 
However, their low frequency cannot explain common 
interindividual differences in CYP3A4 activity. This 
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suggests that the enzyme is rather well preserved as 
a result of selection pressure in the past to preserve 
its function in the metabolism of dietary and other 
environmental factors. Reasons for variations in 
CYP3A4 expression and inducibility could be in 
variations in genes encoding proteins participating 
in the regulation of CYP3A4 transcription of PXR, 
CAR and GR ligands and in the genes controlling 
posttranslational regulation of the protein (192-194).
Similar to CYP3A4, CYP3A7 is a well-conserved 
gene, and up to now one frameshift mutation 
(CYP3A7*3) and one coding polymorphism have 
been identifi ed (CYP3A7*2) (195, 196). CYP3A7*2 
allele has a frequency of 8 %, 28 %, and 62 % in 
Caucasians, Asians, and Africans, respectively, but the 
impact of this polymorphism on foetal drug clearance 
and endogenous substrate metabolism is still unclear. 
CYP3A7-specifi c antibodies show that about 10 % 
of adult livers express signifi cant CYP3A7 protein 
levels that contribute to 24 % of total CYP3A protein 
in these livers.
CYP3A5 has a wide tissue distribution, but is 
expressed at a much lower level than CYP3A4. Only 
about 20 % of people express CYP3A5 in the liver. 
Its expression is generally higher among African-
Americans than Caucasians (197, 198). The most 
common reason for non-expression is a splice site 
mutation. The frequency of variant alleles shows 
interethnic differences with the wild-type CYP3A5*1 
allele more common in Africans than Caucasians and 
Asians (199).
Variability in CYP3A5 expression is a result of 
several SNPs (200), which severely diminish the 
synthesis of functional CYP3A5 like CYP3A5*3,*6 
(41). Substrate specifi city of CYP3A5 is similar to that 
of CYP3A4, but it is less active. CYP3A4 and CYP3A5 
genes share a common regulatory pathway for 
constitutive expression (201). Important substrates of 
CYP3A5 are immunosuppressive drugs cyclosporine, 
tacrolimus, sirolimus, and everolimus, which show a 
large interindividual variability in pharmacokinetic 
properties and a narrow therapeutic index (202). 
Eight independent studies have demonstrated faster 
clearance of drug substrates by variants carrying one or 
two CYP3A5*1 alleles. Some published data suggest 
that CYP3A4, CYP3A5, and CYP3A7 polymorphisms 
affect cyclosporine metabolism, and therefore their 
genotyping could be useful to prospectively optimise 
cyclosporine prescription in transplant recipients 
(203). Recent reports also indicate that dose levels 
of tacrolimus need to be adjusted in transplant 
patients according to CYP3A5 polymorphism (204). 
CYP3A5*1 homozygotes may have higher systolic 
blood pressure due to hormone status (199). Some 
studies explored if individual variations in CYP3A 
may play a role in breast and prostate carcinogenesis 
through modulation of sex hormone metabolite 
levels, or through metabolic activation of exogenous 
carcinogens (205). Certain combined CYP3A4/
CYP3A5 haplotypes showed differential susceptibility 
to prostate cancer. Results obtained suggest that the 
interaction between CYP3A5*3 polymorphisms and 
Table 7 Important drugs which are substrates of enzyme CYP3A4
Drug groups Drugs
Analgesics acetaminophen, alfentanil, codeine, dextromethorphan
Antiarrhythmics dysopiramide, lidocaine, quinidine
Antimicrobials
doxycycline, erytromycin, clarithromycin, clindamycin, ketoconazole, miconazole, 
troleandomycin, HIV-protease inhibitors
Antihistamines astemizole, loratadine, terfenadine 
Anticonvulsant carbamazepine, etosuximide
Antilipemics atorvastatin, fl uvastatin, lovastatin, simvastatin
Antitumour drugs
busulphan, cyclophosphamide, doxorubicin, paclitaxel, tamoxifen, vinblastine, 
vincristine
Ca channel blockers amlodipine, felodipine, nifedipine, nimodipine, verapamil
Steroids estradiol, cortisol, progesterone, prednisone, testosterone
Immunosuppressants cyclosporin, sirolimus, tacrolimus
Cardiotonic glycoside digitoxin
Narcotics methadone, cannabinoids, cocaine, fentanyl
Psychotropic drugs
amphetamines, fl uoxetine, haloperidol, clomipramine, clonazepam, chlorpromazine, 
midazolam, risperidone, triazolam
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androgen metabolism pathway seems to be signifi cant 
in prostate cancer (206). In a study by Plummer et 
al. (207) CYP3A4*1B/CYP3A5*3 haplotype was 
positively associated with prostate cancer risk and 
aggressiveness.
In a multiethnic population study, CYP3A4 -G 
variant (*1B) was more common among African-
Americans than among white men. Race-stratifi ed 
analyses revealed little association between the 
CYP3A4 variant and prostate cancer risk among white 
men, but were limited by the small number of white 
men with the CYP3A4*1B variant. However, *1B/*1B 
genotype was signifi cantly associated with aggressive 
prostate cancer in African-American men (208). 
Females carriers of CYP3A5*1 (high activity enzyme) 
appear to reach puberty earlier, which may affect 
breast cancer risk. Postmortem and in vivo studies have 
provided the fi rst scientifi c evidence that CYP3A5 is 
involved in fentanyl metabolism, and homozygous 
CYP3A5*3 causes impaired metabolism of fentanyl. 
The authors have suggested that genotyping for 
CYP3A4*1B and 3A5*3 variants may help to confi rm 
fentanyl toxicity (209).
CONCLUSION
In everyday life, human body is exposed to a number 
of xenobiotics including drugs, dietary compounds, or 
environmental carcinogens, which are metabolised 
by a variety of enzymes through phase I and phase 
II reactions. These enzymes mainly participate in the 
conversion of xenobiotics to more polar and water-
soluble metabolites which are readily excreted from 
the body. During metabolism of certain xenobiotics, 
a variety of unstable and reactive intermediates can 
be formed, which attack DNA, causing cell toxicity 
and transformation. Individuals differ in the levels 
of expression and catalytic activities of metabolic 
enzymes that activate and/or detoxify xenobiotics 
in various organs, and these phenomena are thought 
to be critical in understanding the background of 
interindividual differences in response to xenobiotics. 
Factors affecting these variations include induction 
and inhibition of enzymes by diverse chemicals and 
by genetic polymorphisms. Inherited DNA sequence 
variations in genes coding for metabolic enzymes 
may have major effects on the effi cacy/toxicity and 
carcinogenic potency of xenobiotics. New methods 
in molecular biology and improved genotyping 
procedures have become available and have been 
applied extensively in association studies between 
metabolic enzyme gene variants and cancer risk. For 
some CYPs (primarily CYP1A1, CYP1A2, CYP1B1, 
and CYP2E1) consistent evidence has been reported 
for the association between polymorphisms and cancer 
susceptibility. The pathways of carcinogen metabolism 
are complex, mediated by the activities of multiple 
genes, as single genes may have a limited impact 
on cancer risk. The knowledge of environmental 
determinants and large studies with detailed exposure 
information are crucial to evaluate reliably any 
moderate genetic effects. Many controversial data are 
present in literature. Positive associations were found 
in certain populations and not confi rmed in others. 
In addition to an expected interethnic variability in 
allele frequencies, variability has also been found 
within an ethnic group, resulting in heterogeneity in 
association studies. Gene-environment interactions 
could be a confounding factor in these studies, with 
controversial fi ndings on cancer risk. Furthermore, 
gene-environment interaction assessment requires 
a large number of samples in order to achieve 
significance. Detection of small genetic effects 
also requires a very large and homogenous sample. 
Small sample size has limitations, particularly after 
stratifi cation with respect to risk factors. Due to small 
samples, estimates may be imprecise, erratic, and 
biased. Therefore certain fi ndings should be taken with 
caution. Replication studies are warranted for further 
conclusions, with careful characterisation of the most 
confounding factors such as diet, including alcohol and 
coffee consumption, smoking or tobacco chewing, age, 
sex, hormonal status, lifestyle, and related diseases. 
Technological advances in molecular biology which 
enable genotyping of a large number of SNPs (DNA 
microarray) and reliable information regarding toxic/
carcinogenic exposure could contribute to obtain more 
conclusive fi ndings in further studies.
Genetic variability of CYP2C9, CYP2C19, 
and CYP2D6 is clinically the most important of 
all CYPs. Predicting therapeutic failure or severe 
adverse drug reactions by genotyping for important 
polymorphisms in key drug-metabolising enzymes 
has a potential to optimize drug choice and/or dose 
at the beginning of therapy, avoiding most adverse 
effects, and decreasing medical costs. Among the 
particularly important treatment regimens affected 
by genetic polymorphisms of CYPs are therapies 
with drugs with a narrow therapeutic index such as 
some antidepressants, anticoagulants, anticonvulsants, 
antidiabetics, antipsychotics, and anticancer drugs. In 
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2007, the United States Food and Drug Administration 
(FDA) announced for the fi rst time that warfarin’s 
(anticoagulant) label would carry new information 
describing the role of genetics in drug dosing. The 
label states that a lower initial warfarin dose “should 
be considered for patients with certain genetic 
variations” (210). Genotyping of CYP2C9 and vitamin 
K-epoxid reductase complex C1 (VKORC1), which is 
warfarins’ target, is recommended before dosing. The 
FDA also approved the microarray-based AmpliChip 
CYP450 test, which analyzes genotypes for CYP2D6 
and CYP2C19, and is another step toward predicting 
the safety and effi cacy of a drug in individual patients 
(211). The FDA has been proactive in a number 
of other ways, including the publication of the 
“Pharmacogenomics Guidance Document” (212).
While pharmacogenomics is a promising approach 
to reduce ADRs and increase therapeutic effi cacy, 
the clinical relevance of genetic variability for drug 
action and metabolism remains to be assessed in 
many cases. It is generally believed that clinicians 
tend to ignore a large amount of new information 
pertaining to pharmacogenetic testing. The main steps 
for successful implementation of pharmacogenetic 
testing should include education of clinicians and all 
others involved in the use and benefi ts of testing, large 
prospective association studies showing the benefi ts 
of pharmacogenomic genotyping, development 
of specific clinical guidelines, and creation of a 
regulatory and ethical framework for testing.
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Sažetak
ULOGA GENSKOG POLIMORFIZMA METABOLIČKIH ENZIMA P450(CYP) KAO ČIMBENIKA 
OSJETLJIVOSTI NA UČINKOVITOST I TOKSIČNOST LIJEKA TE NASTANAK KARCINOMA
Među enzimima I. faze biotransformacije sustav citokroma P450 (CYP) prednjači po katalitičkoj svestranosti 
i pokazuje vrlo visok stupanj polimorfnosti. Istraživanja polimorfi zama gena CYP rezultirala su brojnim 
genetičkim informacijama koje nam pomažu u razumijevanju učinaka ksenobiotika na ljudski organizam. 
Ova superporodica enzima najvažniji je enzimski sustav uključen u biotransformaciju mnogih endogenih 
i egzogenih spojeva uključujući lijekove. Za metabolizam lijekova važan je polimorfi zam CYP2C9, 
CYP2C19, CYP2D6 i CYP3A4/5 enzima. Među najvažnije izoforme odgovorne za biotransformaciju 
različitih kemijskih spojeva a posebno metaboličku aktivaciju prokarcinogena pripadaju CYP1A1, CYP1A2, 
CYP1B1, CYP2E1. Genska analiza ključnih enzima metabolizma lijekova pomaže u predviđanju terapijskog 
učinka ili razvoja štetnih nuspojava lijekova. Stoga primjena genotipizacije u kliničkoj praksi pomaže u 
optimizaciji i individualizaciji terapije i smanjenju medicinskih troškova. Polimorfi zam metaboličkih enzima 
može imati važan učinak na terapiju antidepresivima, antipsihoticima, antikoagulantima, antidijabeticima, 
antitumorskim lijekovima te lijekovima za liječenje ulkusa i HIV-a. Podaci koje donosi toksikogenomika 
istražujući individualne predispozicije za karcinogene, teratogene i druge toksičke učinke ksenobiotika, 
pridonose rasvjetljavanju molekularnih mehanizama kojima kemijski spojevi iz okoliša ili na radnome 
mjestu utječu na nastanak bolesti u ljudi. Postoje značajni dokazi o povezanosti genskih polimorfi zama i 
osjetljivosti za razvoj karcinoma. Metabolički putovi karcinogenih supstancija su kompleksni, posredovani 
aktivnošću različitih gena, dok pojedinačni geni najčešće imaju ograničen učinak. Stoga je multigenski 
pristup, uz uključivanje važnih čimbenika iz okoliša u studijama s velikim brojem ispitanika bitan za 
pouzdanu procjenu rizika od razvoja karcinoma.
KLJUČNE RIJEČI: citokromi P450, farmakogenomika, genotipizacija, individualizacija terapije, 
karcinogeneza, nuspojaveFirtin telabem diurnihiliam obsed se, C. Sp. Tum tatilnem nosultimis et auconcem 
audam sunum or la noximuloctus tudam ment.
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